<!– Schema: Article + FAQPage (embed in for RankMath auto-detection) –>
{
“@context”: “https://schema.org”,
“@type”: “Article”,
“headline”: “Certificate of Analysis for Peptides: The Complete Guide”,
“description”: “A technical guide to reading and verifying a certificate of analysis for peptides, covering HPLC purity, mass spectrometry, endotoxin testing, and red flags.”,
“author”: { “@type”: “Organization”, “name”: “UNIK LAB” },
“publisher”: { “@type”: “Organization”, “name”: “UNIK LAB” },
“dateModified”: “2026-04-02”,
“mainEntityOfPage”: { “@type”: “WebPage” }
}
{
“@context”: “https://schema.org”,
“@type”: “FAQPage”,
“mainEntity”: [
{
“@type”: “Question”,
“name”: “What purity percentage should a peptide COA show?”,
“acceptedAnswer”: { “@type”: “Answer”, “text”: “Research-grade peptides should show ≥95% purity by HPLC. Pharmaceutical-grade compounds target ≥99%. Anything below 95% introduces unquantified impurities that compromise experimental reproducibility and safety.” }
},
{
“@type”: “Question”,
“name”: “What is the difference between HPLC purity and mass spectrometry confirmation?”,
“acceptedAnswer”: { “@type”: “Answer”, “text”: “HPLC measures purity — the percentage of the total sample that is the target compound. Mass spectrometry confirms identity — it verifies the molecular weight matches the expected sequence. A COA needs both. HPLC alone cannot confirm you have the right molecule, and MS alone cannot tell you how pure it is.” }
},
{
“@type”: “Question”,
“name”: “Can a supplier fake a certificate of analysis?”,
“acceptedAnswer”: { “@type”: “Answer”, “text”: “Yes. A COA is only as credible as the lab that produced it. Red flags include missing lab names, suspiciously round purity numbers (exactly 99.00%), no batch number traceable to your order, and in-house testing with no third-party verification. Always cross-reference the COA against an independently verified sample when possible.” }
},
{
“@type”: “Question”,
“name”: “What does TFA content mean on a peptide COA?”,
“acceptedAnswer”: { “@type”: “Answer”, “text”: “TFA (trifluoroacetic acid) is a counter-ion used during HPLC purification. High residual TFA affects cell viability in in vitro studies and alters pH in solution. A quality COA will report TFA levels or confirm acetate salt conversion, which is critical for cell culture applications.” }
},
{
“@type”: “Question”,
“name”: “How do I verify that a COA belongs to my specific batch?”,
“acceptedAnswer”: { “@type”: “Answer”, “text”: “Each vial or lyophilized product should carry a batch or lot number printed on the label. This number must appear on the COA. If a supplier sends a generic COA with no lot number, the document is not traceable to your product. Request the batch-specific COA before placing any order.” }
},
{
“@type”: “Question”,
“name”: “Does UNIK LAB provide COAs with every order?”,
“acceptedAnswer”: { “@type”: “Answer”, “text”: “Yes. At UNIK LAB, every peptide order ships with a full batch-specific COA including HPLC chromatogram, mass spectrometry report, and residual solvent data. COAs are accessible in your account portal and can be requested by email for any historical order.” }
},
{
“@type”: “Question”,
“name”: “What is an endotoxin test and when is it required on a peptide COA?”,
“acceptedAnswer”: { “@type”: “Answer”, “text”: “Endotoxin testing (Limulus Amebocyte Lysate / LAL test) measures bacterial lipopolysaccharide contamination. It is required for any peptide intended for injectable in vivo use. Acceptable limits are typically <1 EU/mg for research use and <0.1 EU/mg for clinical applications.” }
}
]
}
body { font-family: -apple-system, BlinkMacSystemFont, ‘Segoe UI’, sans-serif; max-width: 860px; margin: 0 auto; padding: 24px 16px; line-height: 1.75; color: #1a1a1a; }
h1 { font-size: 2rem; line-height: 1.25; margin-bottom: 0.5rem; }
h2 { font-size: 1.5rem; margin-top: 2.5rem; margin-bottom: 0.75rem; }
h3 { font-size: 1.2rem; margin-top: 1.75rem; margin-bottom: 0.5rem; }
p { margin-bottom: 1rem; }
ul, ol { margin-bottom: 1rem; padding-left: 1.5rem; }
li { margin-bottom: 0.4rem; }
table { width: 100%; border-collapse: collapse; margin: 1.5rem 0; }
.toc { background: #f8fafc; border-left: 4px solid #334155; padding: 16px 20px; margin: 1.5rem 0; border-radius: 4px; }
.toc h3 { margin-top: 0; }
.toc ol { margin-bottom: 0; }
.uniklab-callout { background: #f0f7ff; border-left: 4px solid #3b82f6; padding: 16px 20px; margin: 1.5rem 0; border-radius: 4px; }
.warning-box { background: #fff8f0; border-left: 4px solid #f97316; padding: 16px 20px; margin: 1.5rem 0; border-radius: 4px; }
.faq-section h3 { border-bottom: 1px solid #e2e8f0; padding-bottom: 8px; }
.read-time { color: #64748b; font-size: 0.9rem; margin-bottom: 1.5rem; }
a { color: #2563eb; }
strong { color: #0f172a; }
⏱️ Reading time: ~14 min | Updated: April 2, 2026
How to Read a Certificate of Analysis for Peptides — And Why Most Buyers Get This Wrong
Most peptide buyers read the purity number and stop there. That one data point tells you almost nothing about whether a compound is safe, correctly sequenced, or even what the supplier claims it is. A COA is a multi-layer document, and collapsing it to a single percentage is how contaminated, misidentified, or degraded material ends up in research protocols.
At UNIK LAB, we review hundreds of third-party COAs every year — from our own contract testing labs and from documents submitted by researchers asking us to audit competitor materials. The pattern is consistent: the worst documents look fine at a glance. This guide breaks down every component of a legitimate certificate of analysis for peptides, explains what each number means, and shows you exactly which signals reveal whether a document is worth trusting.
Table of Contents
- Why a COA is the only objective checkpoint between synthesis and use
- Every component of a peptide COA, explained
- Reference table: what a full-standard COA must contain
- Reading the HPLC chromatogram
- Mass spectrometry: identity confirmation
- Purity thresholds by application type
- Beyond purity: what the rest of the COA tells you
- 12 red flags that invalidate a COA
- Third-party testing vs. in-house: the difference that matters
- UNIK LAB’s testing standard
- FAQ
Why a COA Is the Only Objective Checkpoint Between Synthesis and Use

Peptide synthesis is a sequential process: each amino acid added in solid-phase synthesis creates a branch point for error. A 20-residue peptide has 19 coupling steps, and each incomplete coupling leaves a deletion sequence — a truncated compound that is structurally similar but biologically different. These deletion sequences do not announce themselves. They dissolve. They look identical to the correct compound in the vial.
The COA exists to answer one question with data: is what is in the vial what the label says it is, at the concentration and purity stated?
No visual inspection tells you this. No supplier reputation tells you this. Only analytical data does.
The significance compounds when you consider that impurities in peptide preparations can have biological activity of their own. A 5% impurity in a 10 mg/mL solution means 0.5 mg/mL of uncharacterized material with unknown receptor affinity, unknown metabolic fate, and unknown toxicity. In cell culture, that 5% can drive false positives that take months to trace back to source. In animal studies, the consequences are worse.
This is why every serious researcher, clinician, or compounding specialist reviews the full COA — not just the headline purity number — before any material touches an experiment.
Every Component of a Peptide COA, Explained
A complete certificate of analysis for peptides is not one test. It is a collection of parallel analyses that together paint a complete picture of quality. Below is each component broken down.
Lot/Batch Number
The lot number is the document’s anchor to physical reality. It ties the COA to a specific synthesis run and purification batch. Without a lot number, the COA could apply to any batch — or no specific batch at all. Before reviewing any other data, confirm the lot number on the COA matches the lot number printed on your vial’s label.
Compound Identity (Name, Sequence, CAS Number)
The COA must state the full amino acid sequence in one-letter or three-letter notation, the formal IUPAC name, and where applicable, the CAS registry number. For modified peptides — acetylated N-termini, amidated C-termini, disulfide bridges, pegylated variants — all modifications must be explicitly noted. A COA that lists only a trade name without sequence data is incomplete.
Molecular Weight
The theoretical molecular weight (calculated from the sequence) and the observed molecular weight (from mass spectrometry) must both appear. A match within instrument tolerance confirms correct synthesis. A discrepancy, even a small one, flags a modification error, oxidation, or contamination.
HPLC Purity (%)
This is the number most buyers focus on — and the most frequently misunderstood. HPLC purity measures the area percentage of the target compound’s peak relative to all peaks in the chromatogram. It does not directly equal mass percentage. It cannot confirm identity. It is a measure of relative chromatographic homogeneity.
HPLC Chromatogram
The raw chromatogram should be included or available on request. A single clean peak with minimal shoulder peaks or trailing indicates high purity. Multiple peaks, asymmetric peak shapes, or late-eluting impurity peaks all require explanation. A purity number without the chromatogram is an assertion, not evidence.
Mass Spectrometry (MS) Report
Mass spectrometry confirms the molecular identity. ESI-MS (electrospray ionization) or MALDI-TOF are the standard methods for peptide identity confirmation. The spectrum should show the expected [M+H]+ and multiply-charged ions (M+2H, M+3H for longer peptides). The observed mass must match theoretical to within ±0.5 Da (or within 50 ppm for high-resolution instruments).
Water Content (Karl Fischer)
Lyophilized peptides absorb atmospheric moisture. Water content affects the true peptide content per milligram — a compound with 10% water content delivers 10% less active material per measured weight. Karl Fischer titration quantifies residual moisture. This number matters for any protocol where precise molar concentration is needed.
Residual Solvents
Synthesis and purification use organic solvents — acetonitrile, methanol, DMF, TFA. Residual levels must meet ICH Q3C guidelines or stated research specifications. High residual acetonitrile changes solubility behavior. High TFA affects cell viability at biologically relevant concentrations.
Endotoxin Testing (LAL Test)
Required for any peptide intended for in vivo injection. The Limulus Amebocyte Lysate (LAL) test detects lipopolysaccharide contamination from gram-negative bacteria — a primary source of septic shock in animal models. Results are reported in endotoxin units per milligram (EU/mg). The threshold for research-grade injectable peptides is typically <1 EU/mg.
Counterion Content
Peptides purified by reverse-phase HPLC using TFA as a modifier are typically supplied as TFA salts. The counterion affects solubility, stability, and biocompatibility. Acetate salt forms are preferred for in vitro and in vivo applications because TFA is cytotoxic at micromolar concentrations in cell culture. The COA must identify the salt form.
Net Peptide Content
This is often the most practically important number — and the one most frequently omitted by low-quality suppliers. Net peptide content accounts for water and counterion weight, giving the actual percentage of the measured mass that is the peptide compound. A vial labeled “10 mg” with a net peptide content of 70% contains 7 mg of peptide and 3 mg of water, salts, and other material. Dosing calculations must use this number.
Reference Table: What a Full-Standard COA Must Contain
Reading the HPLC Chromatogram
The HPLC chromatogram is the most information-dense part of a peptide COA, and it is frequently omitted or presented as a thumbnail too small to read. Demand the full chromatogram, not just the purity percentage calculated from it.
Reverse-phase HPLC separates peptides by hydrophobicity. The compound elutes from the column at a retention time specific to its sequence and modification state. The detector (typically UV at 214 nm for peptide bond absorption) generates a signal that the software integrates into peak areas.
Purity (%) = (area of target peak / total area of all peaks) × 100
The practical limits of this method: HPLC cannot distinguish between your target peptide and a sequence isomer with identical hydrophobicity. Two compounds can co-elute and appear as one peak. This is why HPLC alone is insufficient — mass spectrometry must confirm that the dominant peak is the correct compound.
What to Look For in the Chromatogram
- Peak symmetry: A well-resolved peak has a symmetry factor between 0.8 and 1.2. Significant fronting or tailing indicates column overload or multiple co-eluting species.
- Baseline resolution: Each peak should return to baseline before the next one begins. Partially resolved peaks are integrated together or separately depending on the software settings — a manipulation point that dishonest labs exploit.
- Early eluting peaks: These often represent hydrophilic impurities, counterions, or truncated sequences. They are sometimes excluded from purity calculations by setting integration limits that start after these peaks — artificially inflating the reported purity.
- Late eluting peaks: Hydrophobic impurities, aggregated peptide, or synthesis byproducts with side chain modifications. A clean preparation shows minimal signal after the target peak.
One practical test: take the retention time of the main peak and compare it against a reference chromatogram from a published source for that peptide sequence, if one exists. A 20% difference in retention time (under the same gradient conditions) is a warning sign.
Mass Spectrometry: Identity Confirmation
Mass spectrometry addresses the question HPLC cannot answer: is the dominant peak actually the compound you ordered?
The two methods used for peptide identity confirmation are ESI-MS (electrospray ionization mass spectrometry) and MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight). Both produce spectra showing mass-to-charge (m/z) ratios. For peptides:
- ESI-MS produces multiply-charged ions: [M+H]⁺, [M+2H]²⁺, [M+3H]³⁺. Longer peptides show higher charge states. All observed ions should be consistent with the same molecular formula.
- MALDI-TOF typically produces singly-charged [M+H]⁺ ions. It is faster and commonly used for quality control but has lower mass accuracy than high-resolution ESI.
The observed molecular weight should match the theoretical molecular weight calculated from the sequence. For a correctly synthesized, unmodified peptide with no post-translational modifications or chemical modifications, the match should be within ±0.5 Da for standard instruments and within ±0.01 Da for high-resolution instruments.
Modifications and Mass Shifts
Chemical modifications create predictable mass shifts. N-terminal acetylation adds 42.01 Da. C-terminal amidation subtracts 0.98 Da (replaces –OH with –NH₂). PEGylation adds multiples of 44 Da per ethylene oxide unit. Disulfide bond formation removes 2 Da (loss of 2H). If the COA reports a modification, the observed mass must reflect it precisely.
A COA that reports “Ac-Peptide-NH₂” but shows a mass matching the unmodified linear form has failed identity confirmation. The peptide in the vial is not what the label claims.
Purity Thresholds by Application Type
The minimum acceptable purity is not one fixed number. It depends on the application, the research context, and the regulatory framework governing the work.
In Vitro Cell Culture (≥95%)
The 5% impurity allowance must be assessed against the total peptide concentration used. At a 100 nM assay concentration, 5% impurity represents 5 nM of uncharacterized material. For most receptors, this is below pharmacologically active concentrations. At higher doses (1–10 µM), 5% impurity at 50–500 nM becomes relevant, particularly if the impurity shares structural homology with endogenous ligands.
In Vivo Animal Models (≥97–99%)
Impurities can trigger immune responses, alter the pharmacokinetic profile, and contaminate results attributed to the target peptide. At UNIK LAB, we recommend ≥97% purity for any peptide used in rodent studies and ≥99% for primate studies or long-duration dosing experiments. Endotoxin testing is mandatory regardless of purity for any injectable preparation.
Structural / Biophysical Studies (≥98%)
Crystallography, NMR, and surface plasmon resonance studies are particularly sensitive to impurities that can co-occupy binding sites, disrupt crystal packing, or generate artifact signals. Researchers in these fields often request ≥98–99% purity with explicit confirmation that no co-eluting sequence isomers are present.
Peptide Libraries and Screening (≥75–85%)
High-throughput screening sometimes accepts lower purity because the primary goal is identifying hit compounds, which will later be validated with higher-purity material. However, even in screening contexts, identity confirmation by mass spectrometry remains non-negotiable.
Beyond Purity: What the Rest of the COA Tells You
Purity and mass confirmation are necessary. They are not sufficient. These additional data points reveal dimensions of quality that the standard numbers miss.
Net Peptide Content vs. Labeled Weight
This is the single most commercially important data point that low-tier suppliers omit. A vial labeled “5 mg” contains a lyophilized powder. That powder includes the peptide, water, counterions (TFA or acetate), and trace synthesis residuals. The net peptide content tells you what fraction of that labeled weight is the actual compound.
A typical research-grade peptide has net peptide content of 70–90%. A poorly handled compound, or one with high TFA content and significant moisture uptake, might show 50–60%. If you are dosing at 1 mg/kg in an animal study based on labeled weight from a vial with 55% net peptide content, your actual dose is 0.55 mg/kg. The study is dosed incorrectly, and the results cannot be reliably interpreted.
Ask for this number before every order. If a supplier cannot provide it, treat the labeled weight as an upper bound estimate only.
TFA Salt vs. Acetate Salt
This matters more than most researchers appreciate. TFA is cytotoxic to mammalian cells. Studies have documented cell viability reductions at TFA concentrations achievable from peptide solutions reconstituted at routine assay concentrations. The Sigma Aldrich technical literature from 2015 and subsequent replication work both show statistically significant viability effects of TFA at concentrations ≥0.1% — concentrations that can be reached from TFA-salt peptides at micromolar working concentrations in small assay volumes.
Acetate counterion exchange is a standard procedure that most GMP-grade and research-grade suppliers offer. The process slightly reduces yield but eliminates the TFA interference. For any cell-based assay, COA documentation of acetate salt form is a quality indicator worth requiring.
Sterility and Bioburden
For in vivo injectable peptides, sterility testing (USP <71> or equivalent) and bioburden testing should accompany the endotoxin data. Sterility testing detects viable microorganisms; endotoxin testing detects their shed membrane components. Neither test is a substitute for the other. A sterile preparation can still fail endotoxin testing if gram-negative bacteria were present during synthesis and lysed.
Appearance and Physical Description
The COA should describe the physical form: white to off-white lyophilized powder is standard for most peptides. Yellow, gray, or brown discoloration can indicate oxidation, incomplete deprotection, or contamination. This is a simple visual checkpoint that takes 10 seconds and catches obvious quality failures before any analytical testing is needed.
12 Red Flags That Invalidate a COA
After reviewing thousands of COAs, these are the patterns that reliably predict low-quality or fraudulent documentation.
- No lot number or a lot number that does not match your vial. The document is not yours.
- Purity listed as exactly 99.00% or 100.00%. Real analytical data has decimal noise. Round numbers are copy-paste artifacts.
- HPLC chromatogram absent or thumbnail-only. The supplier does not want you to examine the peak profile.
- No mass spectrometry data. Identity is unconfirmed regardless of what the purity says.
- Testing laboratory listed as “internal” with no verifiable name. In-house testing without independent verification is unauditable.
- Net peptide content absent. You cannot dose accurately without it.
- Salt form not disclosed. TFA vs. acetate is material information for cell work.
- Endotoxin data absent for an injectable peptide. This is a safety-critical omission.
- COA date predates your order by more than 18 months. Peptides degrade. Stability data has limits.
- Sequence listed only by trade name. You cannot verify what compound was tested.
- HPLC method not specified. Purity numbers are meaningless without knowing the column, gradient, and detection wavelength. Different methods produce different purity numbers for the same compound.
- Mass deviation >1 Da not explained. This could indicate oxidation (+16 Da), deamidation (+1 Da), or incorrect synthesis.
Third-Party Testing vs. In-House Testing: The Difference That Matters
When a supplier tests their own material and issues their own COA, there is a structural conflict of interest. The lab has a financial incentive to report acceptable results. This does not mean in-house COAs are fraudulent — many large, reputable manufacturers maintain internally accredited QC labs with higher standards than external contract labs. But it does mean the verification architecture is different, and the burden of trust falls on the supplier’s reputation and accreditation, not on independent corroboration.
Third-party COAs are issued by a laboratory with no financial interest in the result. The contract lab charges for testing regardless of whether the material passes or fails. Their ISO 17025 accreditation depends on issuing accurate results, not favorable ones. The COA they issue is verifiable: you can contact the lab directly, provide the lot number, and ask them to confirm whether the test was run.
This verification step is available to any buyer. If a supplier claims their material was tested by a named third-party lab, a phone call or email to that lab can confirm it. Suppliers who fabricate third-party COAs do not survive this check — and some have been caught exactly this way.
At UNIK LAB, independent third-party testing is the baseline, not the premium. Our contract testing partners are ISO 17025 accredited and named explicitly in every COA. Full documentation on our testing protocols is available in our research section.
UNIK LAB’s Testing Standard
At UNIK LAB, we build our documentation stack around one principle: a researcher should be able to reproduce the quality verification independently if they choose to. That means every data point we report has a method, an instrument, and an accredited lab behind it.
Our standard COA package for every peptide in our product catalog includes:
- Full amino acid sequence with all modifications explicitly notated
- HPLC purity by reverse-phase analysis with full chromatogram included (C18 column, UV 214 nm, acetonitrile/water gradient)
- ESI-MS identity confirmation with spectrum (high-resolution, ±0.01 Da tolerance)
- Karl Fischer water content determination
- Net peptide content calculated and reported
- Counterion identification (TFA vs. acetate, documented post-ion exchange where applicable)
- Residual solvent screen by headspace GC
- Endotoxin by recombinant Factor C (rFC) assay for all injectable-grade material
- Lot-specific document ID traceable to batch synthesis records
Researchers who want to go deeper — requesting the raw instrument data files, the synthesis batch records, or the stability study data for a specific compound — can make that request through our research documentation portal. We maintain sample retention at -80°C for 24 months post-synthesis for all batches, enabling retesting if a quality dispute arises.
This level of documentation is not common across the peptide supplier space. We know that. It reflects the choice to build infrastructure for research institutions where traceability and reproducibility are requirements, not preferences. If you are evaluating suppliers for a long-term institutional relationship, the documentation standards are where the real differentiation lives — not in marketing claims.
Storing Your Peptides to Keep COA Data Valid
The COA documents the compound at the time of testing. Storage conditions determine whether that quality is maintained. A 98% pure peptide stored improperly can degrade to 85% in three months. The COA is then a historical document, not a current quality statement.
Standard guidance: lyophilized peptides should be stored at -20°C in a dry, oxygen-free environment. Single-use aliquots prepared before the first reconstitution prevent repeated freeze-thaw cycles that accelerate oxidation and aggregation. For peptides containing methionine, cysteine, tryptophan, or asparagine, stability is a particular concern — these residues are oxidation-prone or subject to hydrolysis under non-optimal conditions.
When a peptide has been in storage for more than 12–18 months, consider re-testing purity before use in critical experiments, particularly if the compound is temperature-sensitive or was stored sub-optimally at any point. The analytical cost of a single HPLC run is trivial against the cost of a failed experiment attributed to the wrong variable.
The COA in the Context of Regulatory and Institutional Compliance
Increasingly, institutional review boards, ethics committees, and research compliance offices require COA documentation as part of protocol submission for animal studies and clinical research. The requirements vary by jurisdiction and institution, but the direction is consistent: less tolerance for undocumented materials.
In the EU, peptides used in GLP (Good Laboratory Practice) studies must meet defined purity, identity, and stability criteria, and the analytical documentation must be retained as part of the study archive. In the US, similar requirements apply under FDA 21 CFR Part 58 for GLP compliance.
Even outside formal regulatory frameworks, university institutional animal care and use committees (IACUCs) and biosafety committees are asking for purity and endotoxin documentation with increasing frequency. Suppliers who cannot provide complete COA documentation are functionally incompatible with these institutional requirements.
Sourcing from a supplier whose documentation infrastructure matches institutional requirements prevents compliance problems before they arise, not after a protocol has been submitted and a gap is discovered.
How to Request and Archive COAs Systematically
Lab management of COA documentation is a practical problem that scales poorly if handled informally. Researchers who email back and forth requesting COAs, store PDFs in unsorted download folders, or rely on memory to associate a COA with a specific vial create reproducibility risks that surface during manuscript preparation and peer review.
A minimal systematic approach:
- Request the COA before ordering, not after. Confirm that lot-specific documentation is available for the exact material you will receive.
- File COAs by lot number, linked to the corresponding purchase order and storage location. A spreadsheet mapping lot number → vial location → COA file path takes 10 minutes to create and saves significant time when a reviewer asks for it 18 months later.
- Record the COA receipt date separately from the synthesis date. These can differ by months for stored catalog compounds.
- Check the testing date against your planned use window. For stability-sensitive compounds, testing date + compound half-life under storage conditions = effective expiration of the quality guarantee.
- Keep original PDF copies, not screenshots or printouts. Instrument data embedded in original PDF files can sometimes be extracted and verified; screenshots cannot.
Frequently Asked Questions
What purity percentage should a peptide COA show?
Research-grade peptides should show ≥95% purity by HPLC. Pharmaceutical-grade compounds target ≥99%. Anything below 95% introduces unquantified impurities that compromise experimental reproducibility and safety. For in vivo injectable use, the practical minimum is ≥97%, with endotoxin testing required regardless of purity grade.
What is the difference between HPLC purity and mass spectrometry confirmation?
HPLC measures purity — the percentage of the total sample that is the target compound’s chromatographic peak. Mass spectrometry confirms identity — it verifies the molecular weight matches the expected sequence. A complete COA needs both. HPLC alone cannot confirm you have the right molecule. MS alone cannot tell you how pure it is. The two analyses are complementary, not interchangeable.
Can a supplier fake a certificate of analysis?
Yes. A COA is only as credible as the lab that produced it. Red flags include missing lab names, suspiciously round purity numbers (exactly 99.00%), no batch number traceable to your order, and in-house testing with no third-party verification. If a third-party lab is named, you can contact that lab directly to confirm they ran the test. This is the most reliable verification step available to buyers.
What does TFA content mean on a peptide COA?
TFA (trifluoroacetic acid) is a counter-ion used during HPLC purification. High residual TFA affects cell viability in in vitro studies at micromolar concentrations and alters solution pH. A quality COA will report the salt form or confirm acetate counterion exchange, which is critical for any cell culture application. Suppliers who do not report salt form are omitting material information.
How do I verify that a COA belongs to my specific batch?
Each vial or lyophilized product should carry a batch or lot number printed on the label. This number must appear on the COA. If a supplier sends a generic COA with no lot number, the document cannot be traced to your specific product. Request the batch-specific COA before placing any order, and confirm the lot number matches before use.
Does UNIK LAB provide COAs with every order?
Yes. At UNIK LAB, every peptide order ships with a full batch-specific COA including HPLC chromatogram, mass spectrometry report, and residual solvent data. COAs are accessible in your account portal and can be requested by email for any historical order. For injectable-grade material, endotoxin data is included automatically. Extended documentation — raw instrument files, stability data, synthesis batch records — is available on request through our research portal.
What is an endotoxin test and when is it required on a peptide COA?
Endotoxin testing measures bacterial lipopolysaccharide (LPS) contamination using the Limulus Amebocyte Lysate (LAL) or recombinant Factor C (rFC) assay. It is required for any peptide intended for injectable in vivo use, where endotoxins trigger systemic inflammatory responses that confound experimental results. Acceptable limits are typically <1 EU/mg for research-grade in vivo use and <0.1 EU/mg for GLP or clinical applications.
The Bottom Line
A certificate of analysis for peptides is not a formality. It is the only objective evidence that the compound in the vial is what the label claims, at the quality the protocol requires. Reading it properly — verifying the lot number, examining the chromatogram, confirming mass, checking net peptide content and salt form — takes less than five minutes per compound. The alternative is running experiments on uncharacterized material and spending months troubleshooting results that trace back to the starting material.
The COA review habit is one of the highest-leverage quality practices in peptide research. It costs nothing once the skill is built. The experiments it protects are worth orders of magnitude more.
Every compound in the UNIK LAB catalog ships with full documentation. If you have questions about the analytical methods behind our COAs, or want to discuss documentation requirements for a specific protocol, our scientific team is available through the research contact form.
References
- Verbeke F, Bracke N, Debunne N, Wynendaele E, De Spiegeleer B. Peptide purity and counter ion determination. J Pharm Biomed Anal. 2020;186:113300. PMID: 32325333
- D Agostino BA, Stallberg-White C, Bhatt HG. HPLC-based peptide analysis: method development and validation for pharmaceutical quality control. J Chromatogr A. 2018;1564:1-10.
- United States Pharmacopeia. USP General Chapter <621> Chromatography — guidelines for system suitability testing and method validation in peptide analysis.
- European Pharmacopoeia 11.0. Peptides produced by chemical synthesis: monograph 2034. Quality standards for endotoxin testing (LAL, 2.6.14) and mass spectrometric identification.
